CATABASIS PHARMACEUTICALS IN's ticker is CATB and the CUSIP is 14875P107. A total of 26 filers reported holding CATABASIS PHARMACEUTICALS IN in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $1,606,000 | -16.6% | 2,008,192 | 0.0% | 0.38% | -45.0% |
| Q2 2018 | $1,925,000 | -47.0% | 2,008,192 | 0.0% | 0.68% | -81.6% |
| Q1 2018 | $3,635,000 | -11.4% | 2,008,192 | -27.0% | 3.72% | -9.0% |
| Q4 2017 | $4,101,000 | -29.7% | 2,752,488 | 0.0% | 4.08% | -14.0% |
| Q3 2017 | $5,835,000 | +50.3% | 2,752,488 | 0.0% | 4.75% | +33.1% |
| Q2 2017 | $3,881,000 | -11.9% | 2,752,488 | 0.0% | 3.57% | +8.8% |
| Q1 2017 | $4,404,000 | -55.7% | 2,752,488 | 0.0% | 3.28% | -49.9% |
| Q4 2016 | $9,937,000 | -41.4% | 2,752,488 | 0.0% | 6.54% | -37.2% |
| Q3 2016 | $16,955,000 | +66.5% | 2,752,488 | 0.0% | 10.42% | +17.0% |
| Q2 2016 | $10,184,000 | -26.6% | 2,752,488 | 0.0% | 8.91% | -14.5% |
| Q1 2016 | $13,873,000 | -36.4% | 2,752,488 | 0.0% | 10.42% | -31.9% |
| Q4 2015 | $21,827,000 | -2.0% | 2,752,488 | 0.0% | 15.30% | +19.4% |
| Q3 2015 | $22,268,000 | -33.7% | 2,752,488 | 0.0% | 12.81% | -13.4% |
| Q2 2015 | $33,608,000 | – | 2,752,488 | – | 14.78% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 2,857,667 | $10,573,000 | 10.68% |
| Clarus Ventures, LLC | 2,752,488 | $10,184,000 | 8.91% |
| Rhenman & Partners Asset Management AB | 345,100 | $1,277,000 | 0.23% |
| SPHERA FUNDS MANAGEMENT LTD. | 203,243 | $752,000 | 0.20% |
| Camber Capital Management LP | 1,000,000 | $3,700,000 | 0.18% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 643,580 | $2,381,000 | 0.09% |
| FT Options LLC | 15,059 | $56,000 | 0.05% |
| FRED ALGER MANAGEMENT, LLC | 86,782 | $321,000 | 0.00% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 27,700 | $102,000 | 0.00% |
| FIRST NEW YORK SECURITIES LLC /NY | 750 | $2,775,000 | 0.00% |